Octave Bioscience Inc

Octave Bioscience Inc is a Menlo Park, California biotechnology company founded in 2014 that applies precision medicine and data analytics to the care of patients with neurodegenerative disease, beginning with multiple sclerosis (MS). Its Comprehensive Care Platform is described as a quantitative, objective measurement system intended to expand clinical insight in neurodegenerative disease, providing multiple layers of information and a longitudinal view of disease progression.

Sources characterize Octave as a clinical platform developer that generates, analyzes and combines data to create an integrated, multi-dimensional approach to MS care. The stated aims are to reduce total cost of care by optimizing medication use and healthcare utilization, and to help pharmaceutical companies optimize the full lifecycle of drug discovery, development, clinical trials and post-marketing activity using real-world evidence. A named product referenced in press coverage is the Octave MSDA Test, described in an independent study as an objective measure for distinguishing true MS relapse from pseudoexacerbation.

Classification data attached to the company includes artificial intelligence and analytics technology, a platform model with recurring software revenue, enterprise customers, and diagnostics/healthcare as the main product area, with biotech and healthtech tags and industry codes spanning software publishing, biotechnology R&D and health services.

Business model

Octave develops a clinical/care platform rather than a single point product, generating, analyzing and combining patient data to support multiple sclerosis care. Sources describe the model as platform-based with recurring, software-oriented revenue sold to enterprise customers, with diagnostics and healthcare as the main product category. Stated value propositions include lowering total cost of care by optimizing medication use and healthcare utilization for care providers and payers, and supporting pharmaceutical companies across drug discovery, development, clinical trials and post-marketing real-world evidence.

Classification data describes the revenue model as recurring and software-based, with enterprise customers.

Traction

Aggregator data reports 92 employees as of 5 February 2024 and $91 million total funding raised as of 15 November 2023.

Latest developments

Press mentions listed by a secondary-market platform report an independent study establishing the Octave MSDA Test as an objective measure to distinguish true MS relapse from pseudoexacerbation (July 2026) and the appointment of Zachary Fernandes as Vice President of Business Development to scale strategic partnerships (May 2026). Note that other press mentions listed on the same page concern a Hexagon government-technology spin-off also named Octave and are not attributable to this company.